Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Methods of Nuclear Reprogramming01:24

Methods of Nuclear Reprogramming

2.2K
Nuclear reprogramming is a process of transforming one cell type into an unrelated cell type by epigenetic changes that alter the cell’s original gene expression pattern. Such epigenetic changes force cells to express a different set of genes, which play a significant role in inducing transformation into other cell types. Nuclear reprogramming offers applications in reproductive cloning for livestock propagation and regenerative medicine — developing patient-specific cells for...
2.2K
Somatic to iPS Cell Reprogramming01:29

Somatic to iPS Cell Reprogramming

2.8K
Reprogramming alters the gene expression in somatic cells, transforming them into induced pluripotent stem (iPS) cells over several generations. Scientists can reprogram cells by introducing genes for four transcription factors—Oct4, Sox2, Klf4, and c-Myc (OSKM) by viral or non-viral methods. These factors are also known as Yamanaka factors after Shinya Yamanaka, who first generated iPS cells using mouse skin cells. Yamanaka was awarded the Nobel Prize in Physiology or Medicine in 2012...
2.8K
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

4.1K
Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
4.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Dual Channel of Time-Coded Fluorescence Materials Constructed by Europium-Dynamic Covalent Surfactant and Carbon Quantum Dots for Information Encryption.

Langmuir : the ACS journal of surfaces and colloids·2026
Same author

Anti-Inflammatory Cytokine Signatures in Primary Glaucoma Subtypes: Diagnostic and Pathophysiological Insights From IL-36Ra, IL-37, and IL-38.

Journal of ophthalmology·2026
Same author

Caregiver guilt as an underrecognised burden in family cancer caregiving: a scoping review and implications for palliative care support.

BMC palliative care·2026
Same author

Breathing new life into T-cell receptor-engineered T-cell therapy in solid tumors: enhancing strategies to expand the universality of precision therapy.

Experimental hematology & oncology·2026
Same author

Smart Pickering Emulsions Co-Stabilized by Chalcogenoviologen Surfactants and Single-Atom Pt-Decorated g-C<sub>3</sub>N<sub>4</sub> for Switchable Biphasic Photocatalysis†.

Journal of the American Chemical Society·2026
Same author

Spatial distribution of per- and polyfluoroalkyl substances in the Yellow River basin: Role of suspended sediment on the PFAS partition and accumulation.

Journal of hazardous materials·2026
Same journal

Redefining first-line standards: The role of next-generation HER2-Targeted therapies in HER2-positive metastatic breast cancer.

Biochimica et biophysica acta. Reviews on cancer·2026
Same journal

Organoid-based platforms for oncolytic virus discovery and optimization: Bridging in vitro innovation and clinical translation.

Biochimica et biophysica acta. Reviews on cancer·2026
Same journal

Targeting transcriptional and post-transcriptional pathways in head and neck cancer.

Biochimica et biophysica acta. Reviews on cancer·2026
Same journal

Post-transcriptional regulation in cancer chemoresistance.

Biochimica et biophysica acta. Reviews on cancer·2026
Same journal

Ferroptosis in the tumor immune microenvironment: A double-edged sword in immunotherapy.

Biochimica et biophysica acta. Reviews on cancer·2026
Same journal

Neural-tumor crosstalk in driving tumor metabolic reprogramming.

Biochimica et biophysica acta. Reviews on cancer·2026
See all related articles

Related Experiment Video

Updated: Mar 9, 2026

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
04:01

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Published on: March 15, 2024

2.1K

Reprogramming ferroptosis in MDSCs: For state-dependent immunotherapy combinations.

Yawen Li1, Yuguang Zhao1

  • 1Cancer Center, The First Hospital of Jilin University, Changchun, Jilin 130021, China.

Biochimica Et Biophysica Acta. Reviews on Cancer
|March 7, 2026
PubMed
Summary
This summary is machine-generated.

Targeting ferroptosis in myeloid-derived suppressor cells (MDSCs) can modulate antitumor immunity. Strategies include limiting immunosuppressive mediators during sublethal stress or inducing lethal ferroptosis to enhance immune activation and immunotherapy synergy.

Keywords:
FerroptosisFerroptosis immunomodulation windowImmunosuppressionMDSCsTumor immunotherapy

More Related Videos

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.8K
Reprogramming Mouse Embryonic Fibroblasts with Transcription Factors to Induce a Hemogenic Program
11:00

Reprogramming Mouse Embryonic Fibroblasts with Transcription Factors to Induce a Hemogenic Program

Published on: December 16, 2016

7.7K

Related Experiment Videos

Last Updated: Mar 9, 2026

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics
04:01

Author Spotlight: Tracing the Ferroptotic Signatures and Cell Death Dynamics in Medulloblastoma for Advanced Therapeutics

Published on: March 15, 2024

2.1K
Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells
10:04

Tractable In Vivo Reprogramming of Tumor Cells to Type 1 Conventional Dendritic Cell-like Cells

Published on: August 1, 2025

1.8K
Reprogramming Mouse Embryonic Fibroblasts with Transcription Factors to Induce a Hemogenic Program
11:00

Reprogramming Mouse Embryonic Fibroblasts with Transcription Factors to Induce a Hemogenic Program

Published on: December 16, 2016

7.7K

Area of Science:

  • Immunology
  • Cancer Biology
  • Cell Death Mechanisms

Background:

  • Myeloid-derived suppressor cells (MDSCs) play a critical role in tumor immune evasion.
  • Ferroptosis, a regulated form of cell death, impacts MDSC function and antitumor immunity.
  • MDSC-mediated immunosuppression is context-dependent and influenced by ferroptotic stress.

Purpose of the Study:

  • To review the role of MDSC ferroptosis in regulating antitumor immunity.
  • To introduce the "ferroptosis immunomodulation window" concept for therapeutic targeting.
  • To explore strategies for modulating MDSC ferroptosis to enhance cancer immunotherapy.

Main Methods:

  • Review of existing literature on ferroptosis, MDSCs, and antitumor immunity.
  • Analysis of metabolic pathways (ACOD1-itaconate-NRF2, ASAH2) influencing MDSC ferroptosis.
  • Conceptual framework development for therapeutic intervention.

Main Results:

  • Sublethal ferroptosis in MDSCs releases immunosuppressive mediators (PGE₂, oxidized phospholipids), dampening anti-tumor T-cell and NK cell functions.
  • Disrupting specific metabolic pathways sensitizes MDSCs to ferroptosis.
  • Inhibiting ASAH2 induces lethal ferroptosis in MDSCs, enhancing immune activation.

Conclusions:

  • The "ferroptosis immunomodulation window" offers a dual strategy: limiting immunosuppressive mediators or inducing lethal ferroptosis.
  • Targeting MDSC ferroptosis can overcome immunosuppression and synergize with immunotherapy.
  • Further research is needed for targeted delivery systems to control MDSC ferroptosis.